New stem cell approach aims to beat lymphoma without radiation

NCT ID NCT03125642

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests a stem cell transplant procedure for people with Hodgkin or non-Hodgkin lymphoma, including those with HIV. Participants receive high-dose chemotherapy followed by an infusion of their own stem cells. The goal is to see if this radiation-free approach can improve survival and reduce side effects compared to older methods.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
chemotherapy (etoposide, carmustine, cytarabine, melphalan) followed by stem cell transplant
What this could lead to
If successful, this approach could offer a better, radiation-free way to control lymphoma and improve long-term survival for patients, including those with HIV.
What could go wrong
This is a mid-stage trial with only 150 participants, so results may not apply to everyone. The chemotherapy has serious side effects, and the transplant carries risks like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Masonic Cancer Center, University of Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.